Aruna Venkatesan, MD
Dermatology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 5 carriers
- Offices
- 2
Offices
2 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
24 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Venkatesan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$18,644
Medicare paid this office $18,644 for 176 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 107 | $10,220 | $71 |
| Destruction of precancer skin growth, 1 growth | 29 | $1,450 | $40 |
| New patient visit (30+ min) | 21 | $1,051 | $50 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $881 | $68 |
| Short return visit (20+ min) | 23 | $781 | $31 |
See all 7 services
| Return visit (30+ min) | 107 | $10,220 | $71 |
| Destruction of precancer skin growth, 1 growth | 29 | $1,450 | $40 |
| New patient visit (30+ min) | 21 | $1,051 | $50 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $881 | $68 |
| Short return visit (20+ min) | 23 | $781 | $31 |
| Biopsy of related skin growth, first growth | 26 | $588 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $182 | $1 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 60 | More than 73% of doctors who do this |
| Skin biopsy | 30 | More than 66% of doctors who do this |
Who their Medicare patients are
176 Original Medicare patients in 2024. Average age 70 · Under 65 19% · 85 and older 10% · Women 53% · Also on Medicaid 72% · Health risk score 1.75. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 72% · Diabetes 40% · Chronic kidney disease 27% · Coronary heart disease 20% · Heart failure 19% · Depression 15% · Atrial fibrillation 14% · Cancer 13% · COPD 13% · Dementia 9%.
The office billed $229,543, Medicare allowed $29,908 and paid $18,644; for 479 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 176 | 479 | 70 | 1.75 | $229,543 | $18,644 |
| 2023 | 198 | 552 | 70 | 1.44 | $274,577 | $21,954 |
| 2022 | 201 | 574 | 71 | 1.54 | $270,339 | $24,572 |
| 2021 | 209 | 485 | 70 | 1.57 | $224,532 | $23,334 |
| 2020 | 114 | 224 | 68 | 1.75 | $94,002 | $7,692 |
| 2019 | 196 | 527 | 67 | 1.63 | $173,344 | $17,462 |
| 2018 | 86 | 129 | 68 | 1.45 | $44,848 | $2,923 |
| 2017 | 310 | 612 | 69 | 1.62 | $222,559 | $20,650 |
| 2016 | 331 | 847 | 68 | 1.43 | $266,716 | $29,990 |
| 2015 | 379 | 1,016 | 68 | 1.44 | $252,319 | $30,307 |
| 2014 | 441 | 1,233 | 68 | 1.25 | $274,256 | $38,128 |
| 2013 | 208 | 426 | 66 | 1.35 | $83,767 | $16,508 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 81 | $7,835 | $72 |
| Short return visit (20+ min) | 56 | $2,748 | $43 |
| New patient visit (30+ min) | 40 | $2,282 | $57 |
| Destruction of precancer skin growth, 1 growth | 35 | $1,392 | $36 |
| Destruction of skin growth, 1-14 growths | 19 | $1,101 | $52 |
| Biopsy of related skin growth, first growth | 30 | $674 | $22 |
| New patient visit (15+ min) | 17 | $488 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $196 | $1 |
2022: 7 services
| Return visit (30+ min) | 78 | $7,718 | $80 |
| Short return visit (20+ min) | 85 | $4,952 | $54 |
| Destruction of precancer skin growth, 1 growth | 37 | $2,393 | $49 |
| New patient visit (30+ min) | 18 | $1,147 | $64 |
| Biopsy of related skin growth, first growth | 26 | $569 | $21 |
| Short return visit | 15 | $499 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $323 | $2 |
2021: 10 services
| Short return visit (20+ min) | 103 | $6,030 | $53 |
| Return visit (30+ min) | 48 | $5,299 | $84 |
| Destruction of precancer skin growth, 1 growth | 35 | $1,835 | $51 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,284 | $80 |
| New patient visit (30+ min) | 19 | $1,198 | $63 |
| Biopsy of related skin growth, first growth | 36 | $1,028 | $27 |
| Telephone medical discussion with physician, 5-10 minutes | 24 | $863 | $29 |
| Short return visit | 24 | $771 | $32 |
| Destruction of skin growth, 1-14 growths | 11 | $629 | $57 |
| Destruction of precancer skin growth, 2-14 growths | 26 | $169 | $2 |
2020: 4 services
| Short return visit (20+ min) | 42 | $1,830 | $33 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $825 | $41 |
| Return visit (30+ min) | 14 | $506 | $36 |
| Short return visit | 12 | $167 | $14 |
2019: 8 services
| Short return visit (20+ min) | 93 | $5,286 | $43 |
| New patient visit (30+ min) | 34 | $1,916 | $56 |
| Destruction of precancer skin growth, 1 growth | 29 | $1,764 | $48 |
| Biopsy of related skin growth, first growth | 28 | $846 | $27 |
| New patient visit (15+ min) | 20 | $763 | $38 |
| Short return visit | 32 | $673 | $20 |
| Punch biopsy, first skin growth | 13 | $647 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $270 | $2 |
2018: 4 services
| Short return visit (20+ min) | 30 | $690 | $22 |
| Destruction of precancer skin growth, 1 growth | 13 | $544 | $39 |
| Short return visit | 19 | $273 | $14 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $21 | $2 |
2017: 10 services
| Short return visit (20+ min) | 142 | $5,763 | $31 |
| Return visit (30+ min) | 19 | $1,877 | $43 |
| New patient visit (30+ min) | 32 | $1,732 | $54 |
| Destruction of precancer skin growth, 1 growth | 46 | $1,725 | $31 |
| Short return visit | 81 | $1,334 | $15 |
| Biopsy of single growth of skin and/or tissue | 46 | $1,298 | $28 |
| Destruction of skin growth, 1-14 growths | 24 | $1,261 | $48 |
| New patient visit (15+ min) | 25 | $784 | $31 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $242 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $59 | $1 |
2016: 8 services
| Short return visit (20+ min) | 197 | $10,923 | $36 |
| Destruction of precancer skin growth, 1 growth | 58 | $2,913 | $38 |
| Return visit (30+ min) | 19 | $2,538 | $53 |
| Short return visit | 129 | $2,313 | $16 |
| Destruction of skin growth, 1-14 growths | 35 | $2,304 | $54 |
| Biopsy of single growth of skin and/or tissue | 46 | $1,442 | $29 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,137 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $156 | $2 |
2015: 10 services
| Short return visit (20+ min) | 215 | $9,765 | $32 |
| Destruction of precancer skin growth, 1 growth | 65 | $2,997 | $39 |
| Return visit (30+ min) | 21 | $2,893 | $58 |
| Short return visit | 125 | $2,222 | $17 |
| Destruction of skin growth, 1-14 growths | 37 | $2,079 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,829 | $63 |
| Biopsy of single growth of skin and/or tissue | 50 | $1,514 | $29 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,223 | $87 |
| Biopsy of each additional growth of skin and/or tissue | 20 | $462 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $372 | $2 |
2014: 11 services
| Short return visit (20+ min) | 253 | $14,051 | $36 |
| Destruction of precancer skin growth, 1 growth | 60 | $3,160 | $37 |
| Return visit (30+ min) | 28 | $3,032 | $53 |
| Destruction of skin growth, 1-14 growths | 43 | $2,574 | $54 |
| Biopsy of single growth of skin and/or tissue | 73 | $2,553 | $33 |
| New patient visit (30+ min) | 37 | $2,104 | $57 |
| Short return visit | 94 | $1,782 | $19 |
| New patient visit (15+ min) | 28 | $956 | $34 |
| Biopsy of each additional growth of skin and/or tissue | 21 | $555 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 47 | $523 | $2 |
| Injection into skin growth, 1-7 growths | 11 | $280 | $16 |
2013: 9 services
| Short return visit (20+ min) | 108 | $5,436 | $41 |
| New patient visit (30+ min) | 28 | $1,779 | $64 |
| Destruction of precancer skin growth, 1 growth | 28 | $1,556 | $52 |
| Destruction of skin growth, 1-14 growths | 13 | $1,093 | $64 |
| Short return visit | 41 | $945 | $21 |
| Return visit (30+ min) | 11 | $744 | $62 |
| Biopsy of single growth of skin and/or tissue | 17 | $737 | $43 |
| New patient visit (15+ min) | 15 | $651 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $381 | $4 |
Medicaid work
$33,936 in 2024
Medicaid paid $33,936 for 3,029 billed services this clinician did in 2024, up to 167 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,078 | $20,895 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 546 | $9,231 |
| New patient visit (30+ min) | 93 | $2,156 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 44 | $811 |
| Short return visit (20+ min) | 36 | $456 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 24 | $332 |
| TISSUE EXAM BY PATHOLOGIST | 21 | $56 |
| Service | 58 | $0 |
| Medication list documented in medical record (COA) | 1,129 | $0 |
| 2024 | 3,029 | 9 | 167 | $33,936 |
| 2023 | 1,700 | 8 | 97 | $14,579 |
| 2022 | 1,049 | 4 | 106 | $7,831 |
| 2021 | 1,489 | 6 | 79 | $22,260 |
| 2020 | 905 | 8 | 60 | $34,311 |
| 2019 | 3,970 | 9 | 151 | $156,416 |
| 2018 | 3,446 | 7 | 142 | $155,433 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 934 | $7,043 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 349 | $4,143 |
| New patient visit (30+ min) | 127 | $1,647 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 27 | $928 |
| Short return visit (20+ min) | 139 | $703 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 12 | $68 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 14 | $48 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 98 | $0 |
2022
| Return visit (30+ min) | 665 | $4,798 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 243 | $2,308 |
| Short return visit (20+ min) | 109 | $486 |
| New patient visit (30+ min) | 32 | $239 |
2021
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 119 | $9,775 |
| Return visit (30+ min) | 584 | $6,171 |
| Short return visit (20+ min) | 541 | $3,949 |
| New patient visit (30+ min) | 132 | $1,260 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 100 | $1,027 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 13 | $77 |
2020
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 194 | $16,405 |
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 75 | $6,375 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 127 | $5,395 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 161 | $2,259 |
| New patient visit (30+ min) | 96 | $1,948 |
| Short return visit (20+ min) | 176 | $1,079 |
| Return visit (30+ min) | 63 | $715 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 13 | $135 |
2019
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 1,501 | $117,990 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 426 | $18,656 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 904 | $13,010 |
| New patient visit (30+ min) | 196 | $3,159 |
| Short return visit (20+ min) | 636 | $1,932 |
| Return visit (30+ min) | 201 | $1,215 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 15 | $259 |
| Short return visit | 55 | $131 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 36 | $65 |
2018
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 1,395 | $115,320 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 812 | $24,721 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 262 | $9,994 |
| Short return visit (20+ min) | 568 | $2,305 |
| New patient visit (30+ min) | 98 | $1,415 |
| Return visit (30+ min) | 250 | $1,102 |
| Service | 61 | $575 |
Drugs they prescribed that Part D paid
$2,713,279
Pharmacies billed $2,713,279 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,507) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,037 generic and 470 brand-name prescriptions · $2,713,279 in drug cost · 29 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 155 | $572,695 | $3,695 |
| Humira | 75 | $450,650 | $6,009 |
| Skyrizi | 20 | $379,568 | $18,978 |
| Humira | 28 | $357,127 | $12,755 |
| Stelara | 13 | $280,497 | $21,577 |
See all 29 drugs
| Dupixent | 155 | $572,695 | $3,695 |
| Humira | 75 | $450,650 | $6,009 |
| Skyrizi | 20 | $379,568 | $18,978 |
| Humira | 28 | $357,127 | $12,755 |
| Stelara | 13 | $280,497 | $21,577 |
| Cosentyx Sensoready (2 Pens) | 34 | $250,842 | $7,378 |
| Taltz | 20 | $120,632 | $6,032 |
| Otezla | 14 | $61,552 | $4,397 |
| Dupixent | 15 | $55,943 | $3,730 |
| Acitretin | 27 | $13,604 | $504 |
| Tacrolimus | 41 | $3,642 | $89 |
| Betamethasone Diprop Augmented | 66 | $3,144 | $48 |
| Triamcinolone Acetonide | 163 | $2,928 | $18 |
| Fluocinonide | 78 | $2,901 | $37 |
| Ketoconazole | 123 | $2,213 | $18 |
| Fluorouracil | 19 | $1,416 | $75 |
| Calcipotriene | 12 | $1,143 | $95 |
| Fluocinolone Acetonide | 24 | $1,104 | $46 |
| Hydrocortisone | 76 | $1,026 | $14 |
| Clobetasol Propionate | 64 | $938 | $15 |
| Clotrimazole | 50 | $591 | $12 |
| Hydroxyzine | 59 | $495 | $8 |
| Metronidazole | 15 | $434 | $29 |
| Doxycycline Monohydrate | 22 | $428 | $19 |
| Clindamycin Phosphate | 21 | $421 | $20 |
| Nystatin | 24 | $411 | $17 |
| Mupirocin | 42 | $256 | $6 |
| Fluconazole | 17 | $129 | $8 |
| Prednisone | 11 | $71 | $6 |
Year by year
| 2024 | 1,507 | 266 | 0% (0) | 31% | $2,713,279 |
| 2023 | 1,001 | 241 | 0% (0) | 21% | $1,336,260 |
| 2022 | 868 | 220 | 0% (0) | 23% | $740,417 |
| 2021 | 902 | 216 | 0% (0) | 21% | $682,560 |
| 2020 | 710 | 169 | 0% (0) | 22% | $562,378 |
| 2019 | 828 | 216 | None | 20% | $561,276 |
| 2018 | 1,006 | 241 | 0% (0) | None | $666,477 |
| 2017 | 1,175 | 311 | 0% (0) | None | $575,994 |
| 2016 | 1,448 | 324 | 0% (0) | None | $569,283 |
| 2015 | 1,309 | 306 | None | None | $593,368 |
| 2014 | 894 | 211 | None | None | $356,211 |
| 2013 | 182 | 80 | 0% (0) | 15% | $28,948 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Humira | 52 | $371,075 | $7,136 |
| Stelara | 12 | $286,622 | $23,885 |
| Dupixent | 32 | $121,864 | $3,808 |
| Acitretin | 22 | $11,670 | $530 |
| Betamethasone Diprop Augmented | 47 | $4,382 | $93 |
| Tacrolimus | 31 | $4,258 | $137 |
| Mycophenolic Acid | 12 | $3,842 | $320 |
| Triamcinolone Acetonide | 139 | $3,345 | $24 |
| Fluocinonide | 63 | $3,002 | $48 |
| Clobetasol Propionate | 58 | $2,841 | $49 |
| Ketoconazole | 117 | $2,345 | $20 |
| Fluorouracil | 18 | $2,215 | $123 |
| Clindamycin Phosphate | 31 | $1,211 | $39 |
| Doxycycline Monohydrate | 14 | $929 | $66 |
| Metronidazole | 17 | $897 | $53 |
| Hydrocortisone | 83 | $759 | $9 |
| Gabapentin | 17 | $647 | $38 |
| Hydroxyzine | 22 | $626 | $28 |
| Fluocinolone Acetonide | 11 | $591 | $54 |
| Clotrimazole | 12 | $426 | $36 |
| Ammonium Lactate | 12 | $347 | $29 |
| Mupirocin | 27 | $291 | $11 |
| Nystatin | 14 | $272 | $19 |
| Spironolactone | 11 | $100 | $9 |
2022: 20 drugs
| Humira | 21 | $158,404 | $7,543 |
| Cosentyx Pen (2 Pens) | 12 | $75,546 | $6,295 |
| Dupixent | 15 | $50,833 | $3,389 |
| Betamethasone Diprop Augmented | 65 | $5,722 | $88 |
| Fluocinonide | 73 | $3,989 | $55 |
| Tacrolimus | 28 | $3,684 | $132 |
| Triamcinolone Acetonide | 107 | $2,182 | $20 |
| Calcipotriene | 19 | $1,993 | $105 |
| Ketoconazole | 78 | $1,749 | $22 |
| Doxycycline Monohydrate | 28 | $1,544 | $55 |
| Fluorouracil | 11 | $1,528 | $139 |
| Tretinoin | 13 | $1,158 | $89 |
| Betamethasone Dipropionate | 16 | $1,106 | $69 |
| Clindamycin Phosphate | 23 | $844 | $37 |
| Metronidazole | 18 | $759 | $42 |
| Hydrocortisone | 75 | $643 | $9 |
| Fluocinolone Acetonide | 11 | $569 | $52 |
| Nystatin | 24 | $562 | $23 |
| Hydroxyzine | 34 | $368 | $11 |
| Mupirocin | 21 | $128 | $6 |
2021: 19 drugs
| Humira | 45 | $288,605 | $6,413 |
| Cosentyx Pen (2 Pens) | 21 | $140,474 | $6,689 |
| Betamethasone Diprop Augmented | 76 | $6,281 | $83 |
| Fluocinonide | 84 | $4,791 | $57 |
| Tacrolimus | 25 | $3,639 | $146 |
| Calcipotriene | 30 | $2,952 | $98 |
| Tazarotene | 15 | $2,662 | $177 |
| Ketoconazole | 85 | $2,089 | $25 |
| Triamcinolone Acetonide | 116 | $2,049 | $18 |
| Fluorouracil | 11 | $1,683 | $153 |
| Betamethasone Dipropionate | 15 | $1,314 | $88 |
| Clindamycin Phosphate | 37 | $1,090 | $29 |
| Nystatin | 30 | $830 | $28 |
| Nyamyc | 11 | $497 | $45 |
| Spironolactone | 20 | $405 | $20 |
| Doxycycline Monohydrate | 13 | $350 | $27 |
| Hydrocortisone | 51 | $339 | $7 |
| Hydroxyzine | 40 | $237 | $6 |
| Mupirocin | 19 | $96 | $5 |
2020: 19 drugs
| Cosentyx Pen (2 Pens) | 26 | $133,698 | $5,142 |
| Humira | 20 | $112,159 | $5,608 |
| Humira | 12 | $109,701 | $9,142 |
| Betamethasone Diprop Augmented | 70 | $7,108 | $102 |
| Fluocinonide | 68 | $4,990 | $73 |
| Tacrolimus | 13 | $3,788 | $291 |
| Tazarotene | 15 | $3,305 | $220 |
| Calcipotriene | 22 | $2,118 | $96 |
| Triamcinolone Acetonide | 108 | $1,785 | $17 |
| Ketoconazole | 53 | $1,283 | $24 |
| Methotrexate | 19 | $842 | $44 |
| Clindamycin Phosphate | 20 | $559 | $28 |
| Doxepin | 13 | $452 | $35 |
| Azathioprine | 13 | $304 | $23 |
| Hydrocortisone | 43 | $297 | $7 |
| Gabapentin | 11 | $148 | $13 |
| Spironolactone | 17 | $141 | $8 |
| Hydroxyzine | 18 | $115 | $6 |
| Mupirocin | 18 | $105 | $6 |
2019: 16 drugs
| Humira | 27 | $167,712 | $6,212 |
| Cosentyx Pen (2 Pens) | 24 | $119,008 | $4,959 |
| Humira | 13 | $67,355 | $5,181 |
| Betamethasone Diprop Augmented | 64 | $7,501 | $117 |
| Fluocinonide | 84 | $6,180 | $74 |
| Calcipotriene | 35 | $5,401 | $154 |
| Tacrolimus | 17 | $3,492 | $205 |
| Triamcinolone Acetonide | 119 | $1,971 | $17 |
| Ketoconazole | 75 | $1,774 | $24 |
| Metronidazole | 25 | $1,756 | $70 |
| Fluorouracil | 13 | $1,383 | $106 |
| Methotrexate | 22 | $1,265 | $58 |
| Doxycycline Monohydrate | 26 | $1,057 | $41 |
| Hydrocortisone | 85 | $495 | $6 |
| Mupirocin | 17 | $158 | $9 |
| Hydroxyzine | 14 | $110 | $8 |
2018: 24 drugs
| Humira | 48 | $247,030 | $5,146 |
| Humira | 25 | $120,749 | $4,830 |
| Taltz | 11 | $55,965 | $5,088 |
| Otezla | 13 | $41,416 | $3,186 |
| Fluocinonide | 125 | $13,885 | $111 |
| Calcipotriene | 44 | $9,425 | $214 |
| Clobetasol Propionate | 13 | $4,382 | $337 |
| Betamethasone Diprop Augmented | 35 | $4,377 | $125 |
| Tacrolimus | 14 | $3,610 | $258 |
| Triamcinolone Acetonide | 138 | $3,227 | $23 |
| Fluorouracil | 18 | $2,808 | $156 |
| Metronidazole | 31 | $2,678 | $86 |
| Ketoconazole | 86 | $2,622 | $30 |
| Clotrimazole | 12 | $1,466 | $122 |
| Doxycycline Monohydrate | 45 | $1,393 | $31 |
| Clindamycin Phosphate | 17 | $907 | $53 |
| Methotrexate | 13 | $639 | $49 |
| Doxepin | 13 | $591 | $45 |
| Hydrocortisone | 85 | $485 | $6 |
| Gabapentin | 23 | $365 | $16 |
| Hydroxyzine | 24 | $300 | $12 |
| Sulfamethoxazole-Trimethoprim | 21 | $139 | $7 |
| Prednisone | 11 | $122 | $11 |
| Dexamethasone | 11 | $117 | $11 |
2017: 27 drugs
| Humira | 39 | $171,467 | $4,397 |
| Stelara | 12 | $160,244 | $13,354 |
| Humira | 11 | $49,605 | $4,510 |
| Fluocinonide | 183 | $22,073 | $121 |
| Calcipotriene | 38 | $11,736 | $309 |
| Acitretin | 19 | $11,303 | $595 |
| Clobetasol Propionate | 30 | $7,617 | $254 |
| Betamethasone Dipropionate | 34 | $4,408 | $130 |
| Triamcinolone Acetonide | 201 | $3,941 | $20 |
| Ketoconazole | 94 | $3,749 | $40 |
| Tacrolimus | 13 | $3,325 | $256 |
| Fluorouracil | 23 | $2,997 | $130 |
| Elidel | 11 | $2,261 | $206 |
| Desoximetasone | 11 | $2,238 | $203 |
| Metronidazole | 17 | $1,582 | $93 |
| Clindamycin Phosphate | 23 | $1,515 | $66 |
| Methotrexate | 18 | $1,096 | $61 |
| Doxepin | 23 | $628 | $27 |
| Doxycycline Monohydrate | 20 | $593 | $30 |
| Hydrocortisone | 89 | $554 | $6 |
| Hydroxyzine | 37 | $487 | $13 |
| Prednisone | 21 | $266 | $13 |
| Cephalexin | 11 | $130 | $12 |
| Gabapentin | 14 | $130 | $9 |
| Mupirocin | 13 | $128 | $10 |
| Acyclovir | 12 | $126 | $10 |
| Sulfamethoxazole-Trimethoprim | 13 | $98 | $8 |
2016: 30 drugs
| Stelara | 11 | $183,900 | $16,718 |
| Humira | 22 | $86,266 | $3,921 |
| Humira | 19 | $75,607 | $3,979 |
| Fluocinonide | 225 | $23,148 | $103 |
| Calcipotriene | 51 | $15,961 | $313 |
| Acitretin | 15 | $12,879 | $859 |
| Clobetasol Propionate | 39 | $9,896 | $254 |
| Triamcinolone Acetonide | 253 | $6,593 | $26 |
| Elidel | 17 | $5,990 | $352 |
| Betamethasone Dipropionate | 45 | $5,615 | $125 |
| Fluorouracil | 25 | $4,035 | $161 |
| Ketoconazole | 95 | $3,267 | $34 |
| Tretinoin | 16 | $2,728 | $170 |
| Metronidazole | 22 | $2,200 | $100 |
| Clindamycin Phosphate | 30 | $2,075 | $69 |
| Tacrolimus | 13 | $1,674 | $129 |
| Doxycycline Monohydrate | 39 | $1,550 | $40 |
| Methotrexate | 12 | $1,288 | $107 |
| Econazole Nitrate | 14 | $1,098 | $78 |
| Acyclovir | 20 | $868 | $43 |
| Doxepin | 30 | $844 | $28 |
| Hydrocortisone | 122 | $685 | $6 |
| Hydroxyzine | 47 | $463 | $10 |
| Nystatin | 12 | $401 | $33 |
| Sulfamethoxazole-Trimethoprim | 24 | $331 | $14 |
| Prednisone | 13 | $216 | $17 |
| Mupirocin | 17 | $204 | $12 |
| Ammonium Lactate | 12 | $171 | $14 |
| Levocetirizine Dihydrochloride | 14 | $144 | $10 |
| Gabapentin | 11 | $70 | $6 |
2015: 28 drugs
| Stelara | 21 | $265,406 | $12,638 |
| Humira | 28 | $90,592 | $3,235 |
| Enbrel | 12 | $55,574 | $4,631 |
| Humira | 12 | $38,590 | $3,216 |
| Fluocinonide | 234 | $30,366 | $130 |
| Acitretin | 17 | $26,191 | $1,541 |
| Calcipotriene | 33 | $11,746 | $356 |
| Clobetasol Propionate | 31 | $11,413 | $368 |
| Econazole Nitrate | 24 | $5,376 | $224 |
| Fluorouracil | 28 | $5,353 | $191 |
| Triamcinolone Acetonide | 211 | $4,689 | $22 |
| Metronidazole | 30 | $3,676 | $123 |
| Doxycycline Monohydrate | 46 | $2,331 | $51 |
| Fluocinolone Acetonide | 16 | $2,230 | $139 |
| Clindamycin Phosphate | 28 | $2,228 | $80 |
| Methotrexate | 16 | $1,342 | $84 |
| Ketoconazole | 48 | $1,215 | $25 |
| Hydroxyzine | 56 | $1,119 | $20 |
| Doxepin | 28 | $680 | $24 |
| Hydrocortisone | 87 | $566 | $7 |
| Levocetirizine Dihydrochloride | 24 | $412 | $17 |
| Ammonium Lactate | 13 | $330 | $25 |
| Clotrimazole | 17 | $326 | $19 |
| Sulfamethoxazole-Trimethoprim | 28 | $308 | $11 |
| Prednisone | 12 | $233 | $19 |
| Finasteride | 17 | $173 | $10 |
| Cephalexin | 12 | $118 | $10 |
| Gabapentin | 12 | $110 | $9 |
2014: 20 drugs
| Stelara | 16 | $174,485 | $10,905 |
| Humira | 25 | $67,108 | $2,684 |
| Fluocinonide | 150 | $13,380 | $89 |
| Calcipotriene | 23 | $7,296 | $317 |
| Clobetasol Propionate | 33 | $4,196 | $127 |
| Triamcinolone Acetonide | 152 | $3,584 | $24 |
| Fluorouracil | 16 | $3,200 | $200 |
| Clindamycin Phosphate | 27 | $2,767 | $102 |
| Fluocinolone Acetonide | 19 | $2,563 | $135 |
| Doxycycline Hyclate | 11 | $2,315 | $210 |
| Metronidazole | 16 | $1,994 | $125 |
| Econazole Nitrate | 18 | $1,200 | $67 |
| Methotrexate | 16 | $1,006 | $63 |
| Hydrocortisone | 114 | $825 | $7 |
| Ketoconazole | 23 | $792 | $34 |
| Hydroxyzine | 41 | $759 | $19 |
| Doxepin | 31 | $742 | $24 |
| Doxycycline Monohydrate | 15 | $503 | $34 |
| Cephalexin | 16 | $277 | $17 |
| Sulfamethoxazole-Trimethoprim | 14 | $197 | $14 |
2013: 3 drugs
| Fluocinonide | 29 | $1,656 | $57 |
| Triamcinolone Acetonide | 44 | $1,042 | $24 |
| Hydrocortisone | 27 | $184 | $7 |
Money from drug and device companies
$52 in 2025
| 2025 | 1 | 1 | None | $52 |
| 2023 | 2 | 3 | None | $257 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $52 | 1 payment
|
See the published payment
| Abbvie | Meals · 2025-05-09 | Skyrizi | $52 |
See earlier years (2023)
2023: $257
| E.R. Squibb & Sons L.L.C. | Sotyktu | $132 | 2 payments
|
| AbbVie | Skyrizi | $125 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1235457649
- Licence
- CA DO NOT HAVE YET
- Trained
- University of California, San Francisco School of Medicine, 2009
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 751 S Bascom Ave Ste 510, San Jose, CA, 95128
- NPI first listed
- 2010-05-10
- NPI last updated
- 2013-12-18
This is when the NPI record was last certified, not a medical board exam.